Proxy Results Form 8 K

Item 5.07

Submission of Matters to a Vote of Security Holders.

On October 31, 2024, Traws Pharma, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). A total of 2,205,755 shares were represented at the Annual Meeting, which represented a quorum. At the Annual Meeting, the stockholders of the Company voted on the below proposals. The voting results on these proposals were as follows:

Proposal 1. To elect seven directors, each to hold office until the 2025 Annual Meeting of Stockholders and until his or her successor is elected and qualified.

Each nominee for director was elected by a vote of the stockholders as follows:

Nominee		For		Withheld		Broker Non-Votes
Iain Dukes, D.Phil.		2,188,478		17,277		-
Werner Cautreels, Ph.D.		2,190,044		15,711		-
Trafford Clarke, Ph.D.		2,142,499		63,256		-
Luba Greenwood		2,187,813		17,942		-
Nikolay Savchuck Ph.D.		2,190,182		15,573		-
M. Teresa Shoemaker		2,133,667		72,088		-
Jack E. Stover		2,188,884		16,871		-

Proposal 2. To consider and approve, the Amendment and Restatement of the 2021 Incentive Compensation Plan. The proposal was approved by a vote of the stockholders as follows:

For		Against		Abstain		Broker Non-Votes
2,174,776		28,371		2,608		-

Proposal 2. To approve, on an advisory basis, the compensation of our named executive officers. The proposal was approved by a vote of the stockholders as follows:

For		Against		Abstain		Broker Non-Votes
2,177,245		25,527		2,983		-

Proposal 3. To consider and vote upon the ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposal was approved by a vote of the stockholders as follows:

For		Against		Abstain		Broker Non-Votes
2,196,488		7,554		1,713		-

With regard to Proposal 2, the Company's Compensation Committee of the Board of Directors takes note of the results of the advisory "say-on-pay" proposal and expects to consider these results and feedback received from the Company's ongoing stockholder engagement program, among the factors considered in connection with continuing to discharge its responsibilities in setting the compensation of the Company's named executive officers.

Public link

Please use the above public link if you want to share this noodl on another website.